The risk of cardiac and cerebrovascular complications in patients with concomitant cardiovascular diseases who have had COVID-19
- 4 March 2022
- journal article
- research article
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 99 (11-12) , 632-636
Abstract
During the pandemic caused by the SARS-CoV-2 virus, patients with cardiovascular diseases (CVD), which are often found in the population, are a special risk group. Cardiovascular complications after COVID-19 can occur at diff erent periods of the disease. This research describes cardiovascular complications in patients after recovery.The aim of the study was to identify the incidence of new CVD and complications of existing cardiac pathology in patients who recovered from COVID-19.Material and methods. A retrospective, observational study including 370 patients was conducted. All patients underwent telephone consultations within 6 months after the infectious diseases hospital discharge. When new CVDs, complications or anabasis were identifi ed, follow-up visits were initiated.Results. Among 370 patients under the study, concomitant CVD was registered in 249 (67.29%) people, 121 (32.71%) patients had no case history of cardiovascular pathology. In patients with concomitant CVD during the fi rst 6 months after the infectious diseases hospital discharge, 25 (10.04%) new cardiovascular events were registered, which is signifi cantly more frequent than in patients without case history of CVD (n = 1; 0.83%). The number of events described above was more often observed in the fi rst 3 months after discharge, which is statistically signifi cant (p ˂ 0.05). BP destabilization was most often observed (n = 67; 27.2%) as anabasis, which may be associated with an increased level of anxiety in patients. It was also noted that new CVDs, as well as anabasis, developed because of the timely specialized cardiological medical care absence, which probably led to undesirable events due to inability to correct CVD risk factors in time.Conclusions. In patients with concomitant CVD, who have had COVID-19, in contrast to patients without case history of CVD, the risk of developing new cardiovascular events is signifi cantly higher. Patients with CVD deserve the closest attention during the fi rst 3 months after discharge from the infectious diseases hospital.Keywords
This publication has 14 references indexed in Scilit:
- Extra-respiratory manifestations of COVID-19International Journal of Antimicrobial Agents, 2020
- Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and MortalityJAMA Cardiology, 2020
- Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, ChinaJAMA Neurology, 2020
- Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin SystemCirculation Research, 2020
- Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 PandemicJACC, 2020
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational studyThe Lancet Respiratory Medicine, 2020
- COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment optionsCardiovascular Research, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in ItalyJAMA, 2020
- ACE2 in Brain Physiology and Pathophysiology: Evidence from Transgenic Animal ModelsNeurochemical Research, 2018